Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories

Genetic Testing and Molecular Biomarkers

Volumn 14, Issue 1, 2010, Pages 121-125

  Higgs, Jenny ^a   Gambhir, Nikki ^a   Ramsden, Simon C ^a,b   Poulton, Kay ^c   Newman, William G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b National Genetics Reference Laboratory   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; FC RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; STEM CELL FACTOR; THIOPURINE METHYLTRANSFERASE;

ARTICLE; CONTROLLED STUDY; EQUIPMENT; EVIDENCE BASED MEDICINE; FUNDING; GENE IDENTIFICATION; GENETIC RISK; GENETIC SCREENING; GENOTYPE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH SERVICES RESEARCH; HEALTH SURVEY; HISTOCOMPATIBILITY AND IMMUNOGENETICS LABORATORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IRELAND; LABORATORY; MOLECULAR GENETICS LABORATORY; MUTATIONAL ANALYSIS; PERSONNEL MANAGEMENT; PHARMACOGENETICS; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; RISK ASSESSMENT; UNITED KINGDOM;

DATA COLLECTION; GENETIC TESTING; GREAT BRITAIN; HUMANS; IMMUNOGENETICS; LABORATORIES; PHARMACOGENETICS;

EID: 76949100658     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2009.0156     Document Type: Article

References (16)

1. Chung WH, Hung SI, Hong HS, et al. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486.
2. Gardiner SJ, Begg EJ (2005) Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogen Genomics 15:365-369.
3. Gurwitz D, Lunshof JE, Dedoussis G, et al. (2005) Policy Statement: Pharmacogenomics Education: ISP Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Pharmacogenomics J 5:221-225.
4. GurwitzD, Rodríguez-Antona C, Payne K, et al. (2009a) Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet 17:991-998.
5. Gurwitz D, Zika E, Hopkins MM, et al. (2009b) Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics 12:134-141.
6. Higgs JE, Andrews J, Gurwitz D, et al. (2009) Pharmacogenetics education in British medical schools. Genomic Med 2:101-105.
7. House of Lords Science and Technology Committee (2009) Genomic Medicine, second report, vol.1. Stationery Office Ltd., London.
8. Hughes AR, Spreen WR, Mosteller M, et al. (2008) Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 8: 365-374.
9. Kollek R, van Aken J, Feuerstein G, Schmedders M (2006) Pharmacogenetics, adverse drug reactions and public health. Community Genet 9:50-54.
10. Mallal S, Phillips E, Carosi G, et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568-579.
11. Medicines and Healthcare Products Regulatory Agency (2008) Drug safety update. 1:9. Available at www.mhra.gov.uk= Publications=Safetyguidance= DrugSafetyUpdate=CON014505. Accessed July 5, 2009.
12. [NACB] The National Academy of Clinical Biochemistry (2007) Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice. Available at www.aacc.org=members=nacb=lmpg=onlineguide= draftguidelines=pharmacogenetics=pages=default.aspx. Accessed April 4, 2009.
13. Newman W, Payne K (2008) Removing barriers to a clinical pharmacogenetics service. Personalized Med 5:471-480.
14. Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature 405:857-865.
15. Wordsworth S, Papanicolas I, Buchanan J, et al. (2008) Molecular testing for somatic cancer mutations: a survey of current and future testing in UK laboratories. J Clin Pathol 61: 373-376.
16. Sandwell and West Birmingham Hospitals NHS Trust (2009) Pathology News. Available at www.cityassays.org.uk=tpmt .html, Accessed July 5, 2009.